With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

COAST evaluated the efficacy and safety of intravitreally administered 2mg sozinibercept every four or eight weeks in ...

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries. The US Food and Drug Administration (FDA) has approved an ...

Amid the patriotic chest-thumping and sincere efforts of Canadians to do right by their country in the face of the on-again, off-again U.S. tariffs, the humble little Maple Leaf has been working ...

In response to growing consumer demand for transparency and support for Canadian-made goods, retailers across the country are actively identifying products that are either partially or wholly produced ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that ...

Regeneron's sales growth could drop as one of its medicines faces increased competitive pressures. The drugmaker has other growth drivers and a deep pipeline, including a promising gene therapy.